Nemaura Medical to Participate at the Collision Conference in Toronto June 26-29, 2023
2023年6月22日 - 9:00PM
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical
technology company focused on non-invasive wearable sensors and
personalized weight reduction programs, announces that it will be
participating at the upcoming Collision Conference being held at
the Enercare Centre in Toronto, Canada on June 26-29, 2023. The
Collision Conference brings together leading technology companies
and an expected 40,000 attendees and top media representatives.
Nemaura will present live demonstrations of its
wearable daily non-invasive glucose sensor and host 1x1 meetings
with investors and media. The company has developed an AI driven
analytics platform for both Type 2 diabetes prevention and Type 2
diabetes management. These programs are relevant to the estimated
80+ million people with prediabetes and 30+ million people with
Type 2 diabetes in the U.S. alone. Health maintenance programs
augmented with Nemaura’s proprietary daily wear sensors make them a
unique, flexible, and affordable alternative to existing
programs.
About Nemaura
Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercialising non-invasive wearable
diagnostic devices. The Company is currently also commercialising
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, as a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and prediabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the US FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence under a digital healthcare subscription
service as part of its BEAT® diabetes program
www.BEATdiabetes.Life.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding
Forward-Looking Statements:
The statements in this
press release that are not historical facts may constitute
forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual
future results to differ materially from those expressed or implied
by such statements. Those risks and uncertainties include, but are
not limited to, the launch of proBEAT™ in the U.S., risks related
to regulatory status and the failure of future development and
preliminary marketing efforts, Nemaura’s ability to secure
additional commercial partnering arrangements, risks and
uncertainties relating to Nemaura’s and its partners’ ability to
develop, market and sell proBEAT™, the availability of substantial
additional equity or debt capital to support its research,
development and product commercialization activities, and the
success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those
plans and strategies related to both proBEAT™ digital health, and
sugarBEAT®. There can be no assurance that the Company will be able
to reach a part of or any of the global market for CGM with its
products/services. The U.S. Food and Drug Administration (the
“FDA”) reserves the right to re-evaluate its decision that proBEAT™
qualifies as a general wellness product should it become aware of
any issues such as skin irritation or other adverse events from the
device, as well as any misuse impacting patient safety, and any
other reason as the FDA may see fit at its discretion to determine
the product does not fit the definition of a general wellness
product. These and other risks and uncertainties are identified and
described in more detail in Nemaura’s filings with the United
States Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the most recently
completed fiscal year, its Quarterly Reports on Form 10-Q, and its
Current Reports on Form 8-K. Nemaura undertakes no obligation to
publicly update or revise any forward-looking statements.
Media Contacts
Jules AbrahamCORE IR+1 917-885-7378
Nemaura Medical (NASDAQ:NMRD)
過去 株価チャート
から 4 2024 まで 5 2024
Nemaura Medical (NASDAQ:NMRD)
過去 株価チャート
から 5 2023 まで 5 2024